Management of immune haemolytic disease in the fetus.
Although Rh alloimmunization has been successfully reduced in frequency and severity since the implementation of Rh immune globulin, cases still occur. The management of affected pregnancies requires the efforts of a team which includes obstetrics/fetal medicine, the blood transfusion service, haematological support, nursing assistance and neonatology. The aim of antenatal management is to predict whether or not the fetus is severely affected, to correct the fetal anaemia and to deliver the baby at the optimal time. The management has improved markedly with the introduction of high-resolution real-time ultrasound, fetal blood sampling, intravascular fetal blood transfusion and/or intraperitoneal transfusion and meticulous fetal surveillance. With appropriate and timely management in severely alloimmunized patient, the survival rate of affected fetuses in some centres is now about 90%. There is still a need for research into new methods of treatment such as high dose intravenous immunoglobulin, which might non-invasively diminish fetal red cell destruction. Due to the reduced frequency of severe disease, regionalized treatment centres are essential in order to maximize the experience and efficiency of the management teams.
Tannirandorn
Y
Y
Fetal Medicine Unit, Royal Postgraduate Medical School, Queen Charlotte's and Chelsea Hospital, London, UK.
Rodeck
C H
CH
D001789:Blood Group Antigens / Q000276:immunology; D001803:Blood Transfusion / Q000379:methods; D004899:Erythroblastosis, Fetal / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005312:Fetal Blood / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D007231:Infant, Newborn; D007518:Isoantibodies / Q000032:analysis; D015996:Survival Rate
D001789:Blood Group Antigens; D007518:Isoantibodies